AR038044A1 - Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. - Google Patents
Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.Info
- Publication number
- AR038044A1 AR038044A1 ARP020105001A ARP020105001A AR038044A1 AR 038044 A1 AR038044 A1 AR 038044A1 AR P020105001 A ARP020105001 A AR P020105001A AR P020105001 A ARP020105001 A AR P020105001A AR 038044 A1 AR038044 A1 AR 038044A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- optionally substituted
- groups
- mono
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuesto derivado de pirazina que responde a la fórmula (1) y sales, prodrogas, solvatos y formas cristalinas del mismo aceptables para uso farmacéutico, donde R1 y R2 representan independientemente, un grupo C1-6 alquilo, un grupo (amino) C1-4 alquilo, el amino está opcionalmente sustituido por uno o más grupos C1-3 alquilo, un grupo no aromático opcionalmente sustituido C3-15 carbocíclico; un grupo (C3-12 cicloalquil) C1-3 alquilo, un grupo -(CH2)r (fenil)s, donde r es 0, 1, 2, 3, o 4, s es 1 cuando r es 0, de otro modo s es 1 o 2, y los grupos fenilo están opcionalmente sustituidos en forma independiente por uno, dos o tres grupos representados por Z; naftilo, antracenilo, un grupo heterocíclico saturado de 5 a 8 miembros que contiene un N y, opcionalmente, uno de los siguientes: O, S o un N adicional, donde el grupo heterocíclico está opcionalmente sustituido por uno o más grupos C1-3 alquilo, hidroxilo o bencilo, 1-adamantilmetilo, un grupo -(CH2)t Het, donde t es 0, 1, 2, 3 o 4, y la cadena de alquileno está opcionalmente sustituida por uno o más grupos C1-3 alquilo y Het representa un heterociclo aromático opcionalmente sustituido por uno, dos o tres grupos seleccionados entre un grupo a C1-5 alquilo, un grupo C1-5 alcoxilo o halo; o R1 representa H y R2 tiene los valores definidos anteriormente, o R1 y R2, junto con el átomo de N al que están unidos, representan un grupo heterocíclico saturado de 5 a 8 miembros que contiene un N y opcionalmente uno de los siguientes: O, S o un N adicional, donde el grupo heterocíclico está opcionalmente sustituido por uno o más grupos C1-3 alquilo, hidroxilo o bencilo; X es CO o SO2; Y está ausente o representa NH opcionalmente sustituido por un grupo C1-3 alquilo; R3 y R4 representan independientemente fenilo, tienilo o piridilo, cada uno de los cuales está opcionalmente sustituido por uno, dos o tres grupos representados por Z; Z representa un grupo C1-3 alquilo, un grupo C1-3 alcoxilo, hidroxilo, halo, trifluorometilo, trifluorometiltiol, trifluorometoxilo, trifluorometilsulfonilo, nitro, amino, mono o di C1-3 alquilamino, mono o di C1-3 alquilamido, C1-3 alquilsulfonilo, C1-3 alcoxicarbonilo, carboxilo, ciano, carbamilo, mono o di C1-3 alquil carbamilo, sulfamilo y acetilo; y R5 es H, un grupo C1-3 alquilo, un grupo C1-3 alcoximetilo, trifluorometilo, un grupo hidroxi C1-3 alquilo, C1-3 alcoxicarbonilo, carboxilo, ciano, carbamilo, mono o di C1-3 alquilcarbamilo, acetilo, o hidrazidocarbonilo opcionalmente sustituido por R1 y R2, donde R1 y R2 son como se los definió previamente, y con la salvedad de que cuando R1 y R2 , junto con el átomo de N al que están unidos, representan 4-metilpiperazin-1-ilo o R1 representa H y R2 representa metilo o 1-bencilpiperidin-4-ilo; X es CO; Y está ausente y R5 es H; luego R3 y R4 no representan ambos 4-metoxifenilo. También se describen procesos para preparar tales compuestos, intermediarios que se usan en los mismos, el uso de dichos compuestos en la fabricación de medicamentos para el tratamiento de la obesidad, trastornos psiquiátricos y neurológicos y composiciones farmacéuticas que los contienen.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0104330A SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038044A1 true AR038044A1 (es) | 2004-12-22 |
Family
ID=20286429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020105001A AR038044A1 (es) | 2001-12-19 | 2002-12-19 | Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7342019B2 (es) |
| EP (1) | EP1458690B1 (es) |
| JP (1) | JP2005517655A (es) |
| KR (1) | KR20040068286A (es) |
| CN (1) | CN1620438A (es) |
| AR (1) | AR038044A1 (es) |
| AT (1) | ATE354570T1 (es) |
| AU (1) | AU2002352425A1 (es) |
| BR (1) | BR0214989A (es) |
| CA (1) | CA2469786A1 (es) |
| CO (1) | CO5590917A2 (es) |
| DE (1) | DE60218340T2 (es) |
| ES (1) | ES2280599T3 (es) |
| HU (1) | HUP0402026A3 (es) |
| IL (1) | IL162377A0 (es) |
| IS (1) | IS7314A (es) |
| MX (1) | MXPA04005990A (es) |
| NO (1) | NO20043022L (es) |
| NZ (1) | NZ533275A (es) |
| PL (1) | PL369731A1 (es) |
| RU (1) | RU2004116916A (es) |
| SE (1) | SE0104330D0 (es) |
| TW (1) | TW200410694A (es) |
| WO (1) | WO2003051851A1 (es) |
| ZA (1) | ZA200404805B (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
| EP1546115A4 (en) | 2002-09-27 | 2010-08-04 | Merck Sharp & Dohme | SUBSTITUTED PYRIMIDINES |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0302673D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| GB0302671D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| GB0314049D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| US20060135523A1 (en) * | 2003-06-18 | 2006-06-22 | Astrazeneca Ab | 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator |
| GB0314261D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| EP1644335A4 (en) * | 2003-07-11 | 2008-06-04 | Bristol Myers Squibb Co | TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS |
| US7326706B2 (en) * | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| CA2537535A1 (en) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Novel medical use of selective cb1-receptor antagonists |
| US7320805B2 (en) * | 2003-10-01 | 2008-01-22 | Institut National De La Sante Et De La Recherche Medicale | CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver |
| EP1670460B1 (en) | 2003-10-10 | 2014-11-26 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| TW200528102A (en) * | 2003-10-24 | 2005-09-01 | Solvay Pharm Gmbh | Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| CA2543197A1 (en) * | 2003-10-24 | 2005-05-06 | Solvay Pharmaceuticals Gmbh | Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors |
| GB0327331D0 (en) * | 2003-11-25 | 2003-12-31 | Astrazeneca Ab | Therapeutic agents |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| CA2585175A1 (en) | 2004-10-25 | 2006-05-04 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions |
| CN101155781B (zh) | 2005-04-06 | 2012-11-07 | 霍夫曼-拉罗奇有限公司 | 作为cb1逆激动剂的吡啶-3-甲酰胺衍生物 |
| WO2006113704A2 (en) * | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
| US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| MX2009003222A (es) * | 2006-10-04 | 2009-04-06 | Hoffmann La Roche | Derivados de 3-piridinocarboxamida y 2-pirazinocarboxamida como agentes elevadores de colesterol de lipoproteina de alta densidad. |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| BRPI0806312A2 (pt) | 2007-01-04 | 2011-09-06 | Prosidion Ltd | agonistas cgpr piperidina |
| AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
| AR064736A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
| PL2114933T3 (pl) | 2007-01-04 | 2012-02-29 | Prosidion Ltd | Piperydyny jako agoniści GPCR |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
| CN116323583A (zh) | 2020-08-06 | 2023-06-23 | Chdi基金会股份有限公司 | 用于对亨廷顿蛋白成像的杂联芳基化合物和显像剂 |
| WO2024159284A1 (pt) * | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Hidrazidas bloqueadoras de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits |
| WO2024159286A1 (pt) * | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Compostos fenólicos bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH458361A (de) * | 1965-01-15 | 1968-06-30 | Eprova Ag | Verfahren zur Herstellung von Pyrazincarbonsäuren |
| JPS5322529A (en) * | 1976-08-13 | 1978-03-02 | Nippon Soda Co Ltd | Dihydropyrazine derivative and its preparation |
| WO1989004308A1 (en) * | 1987-11-12 | 1989-05-18 | Terumo Kabushiki Kaisha | Pyrazine derivatives and medicinal preparation containing same |
| JPH06501926A (ja) * | 1990-08-06 | 1994-03-03 | 藤沢薬品工業株式会社 | 複素環式化合物 |
| FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
-
2001
- 2001-12-19 SE SE0104330A patent/SE0104330D0/xx unknown
-
2002
- 2002-12-18 KR KR10-2004-7009589A patent/KR20040068286A/ko not_active Application Discontinuation
- 2002-12-18 HU HU0402026A patent/HUP0402026A3/hu unknown
- 2002-12-18 ES ES02788143T patent/ES2280599T3/es not_active Expired - Lifetime
- 2002-12-18 CA CA002469786A patent/CA2469786A1/en not_active Abandoned
- 2002-12-18 EP EP02788143A patent/EP1458690B1/en not_active Expired - Lifetime
- 2002-12-18 CN CNA028281535A patent/CN1620438A/zh active Pending
- 2002-12-18 BR BR0214989-3A patent/BR0214989A/pt not_active IP Right Cessation
- 2002-12-18 JP JP2003552736A patent/JP2005517655A/ja active Pending
- 2002-12-18 NZ NZ533275A patent/NZ533275A/en unknown
- 2002-12-18 WO PCT/GB2002/005742 patent/WO2003051851A1/en active IP Right Grant
- 2002-12-18 AU AU2002352425A patent/AU2002352425A1/en not_active Abandoned
- 2002-12-18 MX MXPA04005990A patent/MXPA04005990A/es unknown
- 2002-12-18 DE DE60218340T patent/DE60218340T2/de not_active Expired - Fee Related
- 2002-12-18 PL PL02369731A patent/PL369731A1/xx not_active Application Discontinuation
- 2002-12-18 RU RU2004116916/04A patent/RU2004116916A/ru not_active Application Discontinuation
- 2002-12-18 US US10/499,054 patent/US7342019B2/en not_active Expired - Fee Related
- 2002-12-18 IL IL16237702A patent/IL162377A0/xx unknown
- 2002-12-18 AT AT02788143T patent/ATE354570T1/de not_active IP Right Cessation
- 2002-12-19 TW TW091136671A patent/TW200410694A/zh unknown
- 2002-12-19 AR ARP020105001A patent/AR038044A1/es not_active Application Discontinuation
-
2004
- 2004-06-16 IS IS7314A patent/IS7314A/is unknown
- 2004-06-17 ZA ZA200404805A patent/ZA200404805B/en unknown
- 2004-07-09 CO CO04065292A patent/CO5590917A2/es not_active Application Discontinuation
- 2004-07-15 NO NO20043022A patent/NO20043022L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005517655A (ja) | 2005-06-16 |
| NZ533275A (en) | 2006-02-24 |
| RU2004116916A (ru) | 2005-11-10 |
| WO2003051851A1 (en) | 2003-06-26 |
| PL369731A1 (en) | 2005-05-02 |
| CN1620438A (zh) | 2005-05-25 |
| NO20043022L (no) | 2004-07-15 |
| CA2469786A1 (en) | 2003-06-26 |
| EP1458690B1 (en) | 2007-02-21 |
| BR0214989A (pt) | 2004-12-14 |
| CO5590917A2 (es) | 2005-12-30 |
| ZA200404805B (en) | 2005-08-15 |
| IL162377A0 (en) | 2005-11-20 |
| US7342019B2 (en) | 2008-03-11 |
| EP1458690A1 (en) | 2004-09-22 |
| TW200410694A (en) | 2004-07-01 |
| SE0104330D0 (sv) | 2001-12-19 |
| HUP0402026A3 (en) | 2005-08-29 |
| MXPA04005990A (es) | 2004-09-27 |
| ES2280599T3 (es) | 2007-09-16 |
| ATE354570T1 (de) | 2007-03-15 |
| US20050032808A1 (en) | 2005-02-10 |
| IS7314A (is) | 2004-06-16 |
| DE60218340D1 (de) | 2007-04-05 |
| DE60218340T2 (de) | 2007-11-29 |
| AU2002352425A1 (en) | 2003-06-30 |
| KR20040068286A (ko) | 2004-07-30 |
| HUP0402026A2 (hu) | 2005-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038044A1 (es) | Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. | |
| AR042658A1 (es) | Derivados de 1,5-diaril-pirrol-3-carboxamida y su uso como moduladores de receptores canabinoides | |
| AR044829A1 (es) | Derivados de bis-4-cloro fenil pirazinas | |
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| AR044825A1 (es) | Derivados de 5,6-diaril-pirazinas-2-carboxamida y -2-sulfonamidas -3-sustituidas como moduladores de cb1 | |
| BRPI0407699A (pt) | Inibidores de rna-polimerase dependente de rna de vìrus de hepatite c e composições e tratamentos que os utilizam | |
| AR044830A1 (es) | Derivados de 4,5 diaril -3-heterociclilpirazin- 2- ester | |
| UY27039A1 (es) | Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-(3-(pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y métodos de producción | |
| AR042659A1 (es) | Derivados de 4-5 diariltiazoles como ligandos de cb-1 | |
| AR035234A1 (es) | Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| CO4810373A1 (es) | Compuestos azapoliciclicos condensados con arilo | |
| AR054184A1 (es) | Derivados de 1,5 difenilpirazol. procesos de obtencion y composiciones farmaceuticas. | |
| RU2007101685A (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения | |
| BRPI0608216A2 (pt) | agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo | |
| NO20045486L (no) | Nye forbindelser og deres anvendelse | |
| AR049487A1 (es) | Compuestos de imidazol sustituidos | |
| AR041297A1 (es) | Derivados de 4-pirrolidino- fenil- bencil eter | |
| AR006360A1 (es) | Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion. | |
| BRPI0408727A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, método para tratar de uma condição ou estado de doença mediados pela atividade da quinase p38 ou mediados pelas citocinas produzidas pela atividade da quinase p38, e, uso de um composto | |
| AR043444A1 (es) | Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2 | |
| AR021662A1 (es) | Derivados de la piperazina, proceso para prepararlos. las composiciones farmaceuticas que los contienen y la utilizacion de las mismas como medicamentoso para la preparacion de medicamentos | |
| AR050947A1 (es) | Derivados de 3,4-dihidro-3-metil-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazina-8-carboxilato | |
| RU2008127260A (ru) | Производные хиназолинона в качестве антагонистов ваниллоидов | |
| AR037611A1 (es) | Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |